ArticlePLOS mental health2024
Cost-effectiveness of automated digital CBT (Daylight) for generalized anxiety disorder: A Markov simulation model in the United States.
Article in PLOS mental health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Digital Cognitive Behavioral Treatment for Generalized Anxiety Disorder: A Randomized Clinical Trial.JAMA network open · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examines the cost-effectiveness and cost-benefit of a fully automated smartphone-delivered digital cognitive behavioral therapy (CBT) intervention for Generalized Anxiety Disorder (GAD). In a simulated Markov model, 100,000 individuals with GAD were studied under one of five (n = 20,000 per arm) treatments (digital CBT [Daylight], individual CBT, group CBT, pharmacotherapy, or no GAD treatment). Model inputs were determined from the literature and included direct treatment costs and disease costs. Net monetary benefit (NMB) determined whether digital CBT is cost-beneficial from both a private payer and societal perspective in the United States in 2020. Digital CBT was found to generate the lowest 12-month total cost ($167.02m) and the second highest number of total quality-adjusted life years (14,711.86). Digital CBT showed a positive NMB relative to each alternative treatment and to no treatment for GAD in both a payer and societal perspective. Relative to no treatment, the average NMB of digital CBT was $1,836.83 from the payer perspective and $4,126.88 from the societal perspective. Digital CBT generates the most value in both a payer and societal perspective, and results were robust to sensitivity analysis with respect to effectiveness, pricing, and attrition parameters.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.